#### **UTILITY PATENT APPLICATION TRANSMITTAL** (Larg Entity)

Docket No. 91301

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission 39

#### TO THE COMMISSIONER FOR PATENTS

**Mail Stop Patent Application** 

P.O. Box 1450 Alexandria, VA 22313-1450
Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:
THERAPY PROBE
and invented by:  François Lacoste, Antoine Tetard, Christian Chaussy and Jean-Yves Chapelon.
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:
Which is a:  Continuation Divisional Continuation-in-part (CIP) of prior application No.:
Which is a:
Continuation Divisional Continuation-in-part (CIP) of prior application No.:
Enclosed are:
Application Elements
1. 🗵 Filing fee as calculated and transmitted as described below
2. Specification havingEighteen 18 pages and including the following:
a. 🗵 Descriptive Title of the Invention
b.   Cross References to Related Applications (if applicable)
c.   Statement Regarding Federally-sponsored Research/Development (if applicable)
d.  Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix .
e. 🗵 Background of the Invention
f. 🗵 Brief Summary of the Invention
g. 🗵 Brief Description of the Drawings (if filed)
h. 🗵 Detailed Description
i. 🗵 Claim(s) as Classified Below
j. 🛮 Abstract of the Disclosure

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 91301

Total Pages in this Submission 39

	Applicati n Elements (Continued)							
3.	$\boxtimes$	Drawing(s) (when necessary as prescribed by 35 USC 113)						
	a.	☐ Formal Number of Sheets						
	b.	☐ Informal Number of Sheets Fifteen (15)						
4.	X	Oath or Declaration						
	a.	☐ Newly executed (original or copy)						
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)						
	c.	☑ With Power of Attorney ☐ Without Power of Attorney						
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).						
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)						
7.	X	Application Data Sheet (See 37 CFR 1.76)						
8.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)						
	a.	☐ Computer Readable Form (CRF)						
	b.	☐ Specification Sequence Listing on:						
		i. CD-ROM or CD-R (2 copies); or						
		ii. 🔲 Paper						
	C.	Statement(s) Verifying Identical Paper and Computer Readable Copy						
		Accompanying Application Parts						
9.		Assignment Papers (cover sheet & document(s))						
10.		37 CFR 3.73(B) Statement (when there is an assignee)						
11.		English Translation Document (if applicable)						
12.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations						
13.		Preliminary Amendment						
14.	X	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)						
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)						
16.	X	Certificate of Mailing						
		☐ First Class ☒ Express Mail (Specify Label No.): EL400002206US						

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 91301

Total Pages in this Submission 39

		Accompanying Application Parts (Continued)					
17.	X	Additional Enclosures (please identify below):					
		Check in the Amount of \$910.00.					
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)					
8.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.					
		Warning					
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.					

### UTILITY PATENT APPLICATION TRANSMITTAL (Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 91301

Total Pages in this Submission 39

#### **Fee Calculation and Transmittal**

		CLAIMS AS FILED						
For	#Filed	#Allowed	#Extra		Rate	Fee		
Ţotal Claims	23	- 20 =	3	×	\$18.00	\$54.00		
Indep. Claims	4	- 3 =	1	x	\$86.00	\$86.00		
Multiple Dependent C	laims (check	if applicable)				\$0.00		
		•			BASIC FEE	\$770.00		
OTHER FEE (specify purpose) \$0.00								
· ·					TOTAL FILING FEE	\$910.00		
<ul> <li>A check in the amount of \$910.00 to cover the filing fee is enclosed.</li> <li>✓ The Director is hereby authorized to charge and credit Deposit Account No. 23-0920 as described below.</li> <li>☐ Charge the amount of as filing fee.</li> <li>☒ Credit any overpayment.</li> <li>☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.</li> <li>☒ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).</li> </ul>								

Page 4 of 4

cc:

Welsh & Katz, Ltd. 120 South Riverside Plaza

Chicago, Illinois 60606

Eric D. Cohen, Reg. No. 38,110

22nd Floor

CERTIFICATE OF	MAIL" (37 CFR 1.10)	Docket No.							
Applicant(s): Lacoste et	al.		91301						
Carried Ma	Filing Date		Crave Add Hair						
Serial No.	Filing Date	Examiner	Group Art Unit						
To Be Assigned	January 14, 2004	To Be Assigned	To Be Assigned						
Invention: THERAPY P	PROBE								
I hereby certify that the	e following correspondence:		.1						
Utility Application Transmittal (Large Entity); Specification Eighteen (18) Pages; Informal Drawings Fifteen (15) Sheets; Unexecuted Declaration and Power of Attorney; Application Data Sheet; Check in the Amount of \$910.00; and Postcard.									
i — , — <del></del>	(Identify type o	of correspondence)							
is being deposited with	the United States Postal Service	e "Express Mail Post Office to Add	dressee" service under 37						
		•							
CFN 1.10 III all elivelo	pe addressed to. Commissioner	for Patents, P.O. Box 1450, Alexa	nuna, VA 22313-1450 on						
January 14, 2004									
	(Date)								
		Daryl Jones	•						
		(Typed or Printed Name of Person Mailin	ng Correspondence)						
		(Signature of Person Mailing Copy	espondence)						
		(Signature of Jerson Maning Cype	csponuciec)						
		EL400002206US							
		(''Express Mail'' Mailing Label	Number)						
Note: Each paper must have its own certificate of mailing.									